Frequently Asked Questions

The U.S. Department of Justice has filed a civil action against Vohra Wound Physicians Management, alleging various schemes to submit false claims for payment to Medicare. Learn more about the ongoing lawsuit and how Health Law Alliance supports wound care providers to avoid legal scrutiny.

On April 4, 2025, the Department of Justice initiated a civil action against Vohra Wound Physicians Management LLC (“Vohra”), one of the largest specialty wound care providers in the nation, alleging multiple violations of the False Claims Act. The lawsuit alleges that Vohra and its founder, Dr. Ameet Vohra, engaged in a complex scheme to overbill Medicare for debridement procedures, many of which were allegedly not performed or were not medically necessary. 

In its complaint, the DOJ alleges wide-ranging efforts to overbill for debridement procedures across the Practice’s locations, including the use of a proprietary EMR system that automatically billed debridement procedures as the highest-reimbursing type of procedure, regardless of procedure type. The system allegedly inserted false clinical observations into patient charts, using pre-programmed text to create the false impression that surgical procedures were performed to evade audit scrutiny. The DOJ further alleged that Vohra intentionally failed to educate its physicians, who were not wound specialists by training, about the different types of debridement procedures and corresponding Medicare payment rules during training, pressuring physicians to perform as many debridements as possible through aggressive revenue goals and targets.

Enhanced Regulatory Oversight: Key Takeaways for Wound Care Providers

The lawsuit is a reminder of the increasing legal and regulatory scrutiny facing providers in 2025. Just last year, CMS initiated a “clawback” initiative aimed at recouping overpayments to providers with a particular emphasis on wound care procedures, citing high rates of incomplete or insufficient documentation and coding errors as common issues. In particular, OIG has signaled its intent to increase its oversight into wound care providers’ billing. In November 2024, OIG announced it would be dedicating significant resources to review Part B payments for skin substitute claims as part of its Work Plan

While wound care has long been a target of federal enforcement activity, wound care practice continues to rapidly evolve, particularly as the aging population increases and new technologies arise. 2025 has already begun to see more widespread federal investigation of wound care practices, meaning wound care providers are under more pressure now than ever before—facing audits, investigations, and even civil and criminal penalties.

Your Partners in Navigating Wound Care’s Changing Landscape

Successfully navigating a complex regulatory environment requires expert legal guidance. With decades of experience helping providers navigate audits, minimize their financial exposure, and defend against overpayment allegations, our team partners with you to address the challenges facing your practice and help ensure your practice is prepared for any situation. 

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>

9th Circuit’s Landmark EKRA Ruling—What Providers Should Know

On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.

Read More >>

Collateral Consequences Mount Quickly After Adverse DEA Inspection

Adverse findings during a DEA inspection can trigger a chain reaction of serious consequences for pharmacies, including increasing fines, suspension or revocation of DEA registrations and pharmacy licenses, costly False Claims Act (FCA) lawsuits, and potential criminal liability.

Read More >>

Heath Law Alliance Secures Reversal of a Medicaid Payment Suspension

Health Law Alliance successfully secured a full reversal of a Medi-Cal payment suspension for a California pharmacy, overturning speculative allegations made by the Department of Health Care Services. This case highlights the firm’s ability to protect healthcare providers against unjust enforcement actions and the critical value of experienced legal counsel in Medicaid and insurance disputes.

Read More >>